Back to search

Article

Polygenic scores for major depressive disorder and depressive symptoms predict response to lithium in patients with bipolar disorder

2018-10-22

Abstract excerpt

<h4>Background</h4> Lithium is a first-line medication for bipolar disorder (BD), but only ~30% of patients respond optimally to the drug. Since genetic factors are known to mediate lithium treatment response, we hypothesized whether polygenic susceptibility to the spectrum of depression traits is associated with treatment outcomes in patients with BD. In addition, we explored the potential molecular underpinning...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2745baf7-2cb8-5e77-87f3-cba7e477afac
DOI
10.1101/449363
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Polygenic scores for major depressive disorder and depressive symptoms predict response to lithium in patients with bipolar disorderDOI 10.1101/449363
Select a neighboring publication to make it the new centre.